Endocrine Abstracts

When faced with patients presenting with gonadal or adrenal insufficiency, whether primary or secondary to pituitary dysfunction, pediatric and adult endocrinologists have a wide range of hormone replacement therapies at their disposal. However, while these treatments often achieve the desired clinical balance, they do not systematically replicate human physiology. Numerous molecules exist, with clinical practices varying considerably between countries and medical teams. These treatments must always be discussed on a case-by-case basis with the patients concerned. For decades, however, few new developments have emerged in the therapeutic field of gonadal or adrenal insufficiency. Undoubtedly, one of the most striking examples of therapeutic innovation concerns congenital adrenal hyperplasia, where the approach has been highly innovative in recent years, with the simple objective of sufficiently suppressing the production of adrenal steroids without causing secondary clinical hypercortisolism in these patients with adrenal insufficiency. We will discuss these therapeutic approaches as well as the interest in considering new markers that could involve a more tissue-specific view of hormone replacement treatments, always with the underlying aim of achieving the desired effects on the different target tissues without inducing significant side effects.